Abstract:
The present invention relates to the use of a sulfonamide compound of formula (I): wherein Ris selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxy, methoxy, ethoxy, morpholino, Ris selected from H, phenyl, substituted phenyl, CN, —SOR, wherein R is phenyl or morpholino, —NC(O)Me, —NC(O)Et, —CHC(O)OMe, CHC(O)OEt, Ris selected from the group consisting of H, NO, NH, halogen, —COOMe, —COOEt, RC(O)N—, morpholino, Ris selected from the group consisting of H, a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, methoxy, ethoxy, propoxy, butoxy, a substituted or unsubstituted phenyl, alkinyl, MeSO—, COOR, wherein R is a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, -MeOC(O)—, a substituted or unsubstituted five or sixmembered aromatic or non-aromatic heterocyclic system with one, two or three heteroatoms, a hetaryl system, a condensed benzoheterocyclic system, X is a linker comprising 2 or 3 atoms, selected from the group consisting of —NH—NH—, —NH—NH—CH2—, ethinyl, —NH—C(O)—CH—, —NH—NH—SO—, —C(O)—NH—CH—, —NH—N═CH—, —NH—N═C(Me)-, a —NH—N═CH— motif being part of a heterocyclic system, preferably a substituted or unsubstituted pyrazole or pyridazine system, and pharmaceutically active salts thereof. Further, the invention relates to the use of these compounds as a medicament, especially for the treatment of cancer.